|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In particular, galectin 4 (LGALS4) was highly and specifically expressed in MOC, but expressed at lower levels in benign mucinous cysts and borderline (atypical proliferative) tumours, supporting a malignant progression model of MOC.
|
16508639 |
2006 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
By comparing the number of RBCs attaching to each tumor cell, we found that cells with high pre-incubation expression levels of galectin-4 attached significantly more RBCs than those with low expression levels (p < 1 × 10<sup>-7</sup>).
|
28293788 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Intravenous injection of a GAL4 regulated bicistronic adenovirus vector constructed to express βG under the control of the PSA promoter (Ad/PSAP‑GV16‑βG) and the application of DOX‑GA3 strongly inhibited tumor growth and prolonged the survival time of tumor‑bearing nude mice.
|
26648021 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
No significant correlation was observed between decreased expression of galectin-4 and the degree of differentiation of the tumor or Duke's state.
|
9310382 |
1997 |
|
Colorectal Carcinoma
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
Surface-bound galectin-4 regulates gene transcription and secretion of chemokines in human colorectal cancer cell lines.
|
28345468 |
2017 |
|
Colorectal Carcinoma
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
Cloning and expression of the mRNA of human galectin-4, an S-type lectin down-regulated in colorectal cancer.
|
9310382 |
1997 |
|
Colorectal Carcinoma
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
Conversely, the expression levels of galectin-4 were significantly lower in CRC samples and its precursor lesions with dysplasia or inflammation.
|
23378274 |
2013 |
|
Colorectal Carcinoma
|
0.070 |
AlteredExpression
|
disease |
BEFREE |
Previously, galectin-4 has been shown to have a role in cancer progression and metastasis and it is found upregulated in many solid tumours, including colorectal cancer (CRC).
|
26681582 |
2016 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
To ensure cancer-specific targeting, efficient delivery, and efficacy, we developed an ovarian cancer-specific construct (Survivin-VISA-hEndoyCD) composed of the cancer specific promoter survivin in a transgene amplification vector (VISA; VP16-GAL4-WPRE integrated systemic amplifier) to express a secreted human endostatin-yeast cytosine deaminase fusion protein (hEndoyCD) for advanced ovarian cancer treatment. hEndoyCD contains an endostatin domain that has tumor-targeting ability for anti-angiogenesis and a cytosine deaminase domain that converts the prodrug 5-fluorocytosine (5-FC) into the chemotherapeutic drug, 5-fluorouracil.
|
22562248 |
2013 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
The ectopic expression of gal-4 in cancer cell lines was used to address its biological function in UC in vitro.
|
28423602 |
2017 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
We show that abrogation of galectin-4 expression promotes cancer cell proliferation and, for the first time, provide evidence that down-regulation of galectin-4 elicits tumor promotion in vitro and in vivo through activation of IL-6/NF-κB/STAT3 signaling.
|
23378274 |
2013 |
|
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Galectin-4 in normal tissues and cancer.
|
15115909 |
2004 |
|
Primary malignant neoplasm
|
0.060 |
AlteredExpression
|
group |
BEFREE |
We show that abrogation of galectin-4 expression promotes cancer cell proliferation and, for the first time, provide evidence that down-regulation of galectin-4 elicits tumor promotion in vitro and in vivo through activation of IL-6/NF-κB/STAT3 signaling.
|
23378274 |
2013 |
|
Primary malignant neoplasm
|
0.060 |
AlteredExpression
|
group |
BEFREE |
To ensure cancer-specific targeting, efficient delivery, and efficacy, we developed an ovarian cancer-specific construct (Survivin-VISA-hEndoyCD) composed of the cancer specific promoter survivin in a transgene amplification vector (VISA; VP16-GAL4-WPRE integrated systemic amplifier) to express a secreted human endostatin-yeast cytosine deaminase fusion protein (hEndoyCD) for advanced ovarian cancer treatment. hEndoyCD contains an endostatin domain that has tumor-targeting ability for anti-angiogenesis and a cytosine deaminase domain that converts the prodrug 5-fluorocytosine (5-FC) into the chemotherapeutic drug, 5-fluorouracil.
|
22562248 |
2013 |
|
Primary malignant neoplasm
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Galectin-4 in normal tissues and cancer.
|
15115909 |
2004 |
|
Primary malignant neoplasm
|
0.060 |
AlteredExpression
|
group |
BEFREE |
The ectopic expression of gal-4 in cancer cell lines was used to address its biological function in UC in vitro.
|
28423602 |
2017 |
|
Malignant neoplasm of colon and/or rectum
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
Surface-bound galectin-4 regulates gene transcription and secretion of chemokines in human colorectal cancer cell lines.
|
28345468 |
2017 |
|
Malignant neoplasm of colon and/or rectum
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
Abrogation of galectin-4 expression promotes tumorigenesis in colorectal cancer.
|
23378274 |
2013 |
|
Malignant neoplasm of colon and/or rectum
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
Cloning and expression of the mRNA of human galectin-4, an S-type lectin down-regulated in colorectal cancer.
|
9310382 |
1997 |
|
Neoplasm Metastasis
|
0.050 |
AlteredExpression
|
phenotype |
BEFREE |
It is well-documented that galectin-4 is upregulated in many types of tumor cells and is involved in metastasis.
|
28293788 |
2017 |
|
Adenocarcinoma
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Through differential screening, virtual reverse northern hybridization and quantitative real-time reverse-transcription-polymerase chain reaction (qRT-PCR) we selected five genes (TncRNA, OCIAD2, ANXA2, TMED4 and LGALS4) that were expressed at significantly higher levels in invasive adenocarcinoma mixed subtype with BAC than in BAC.
|
17054434 |
2007 |
|
Adenocarcinoma
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Galectin-4 (Gal-4) is a member of the galectin family of glycan binding proteins that shows a significantly higher expression in cystic tumors of the human pancreas and in pancreatic adenocarcinomas compared to normal pancreas.
|
23824659 |
2013 |
|
Pancreatic carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
According to subgroup analysis, high levels of galectin-1 were significantly correlated with worse OS in pancreatic cancer (HR, 4.77; 95% CI 2.47-9.21), while high levels of tandem-repeat galectins (galectin-4 or galectin-9) predicted both better OS (HR, 0.63; 95% CI 0.46-0.86) and disease-free survival (DFS) (HR, 0.63; 95% CI 0.48-0.83).
|
31832021 |
2019 |
|
Malignant neoplasm of pancreas
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
According to subgroup analysis, high levels of galectin-1 were significantly correlated with worse OS in pancreatic cancer (HR, 4.77; 95% CI 2.47-9.21), while high levels of tandem-repeat galectins (galectin-4 or galectin-9) predicted both better OS (HR, 0.63; 95% CI 0.46-0.86) and disease-free survival (DFS) (HR, 0.63; 95% CI 0.48-0.83).
|
31832021 |
2019 |
|
Carcinogenesis
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
We generated a Gal4/UAS-based zebrafish model of pancreatic tumorigenesis in which the pancreatic expression of UAS-regulated oncogenes is driven by a ptf1a:Gal4-VP16 driver line.
|
25065594 |
2015 |